Comment on, "T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant"

Hethesh Chellapandian ¹, Sivakamavalli Jeyachandran ²

⁰Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai-77, Tamil Nadu, India.

Neurosurgical Review +

|

October 8, 2024

View abstract on PubMed

Summary

The T2-FLAIR mismatch sign may predict CDKN2A-intact status in IDH-mutant astrocytomas, aiding preoperative diagnosis. Further validation is needed due to study limitations.

Area Of Science

Neuro-oncology
Radiology
Molecular Pathology

Background

Investigating the T2-FLAIR mismatch sign in IDH-mutant, non-enhancing astrocytomas.
Assessing the potential of T2-FLAIR mismatch as an imaging biomarker for CDKN2A status.

Discussion

The study highlights T2-FLAIR mismatch's potential in predicting CDKN2A-intact astrocytomas.
Molecular confirmation via immunohistochemistry and next-generation sequencing enhances diagnostic accuracy.

Key Insights

T2-FLAIR mismatch shows promise as a non-invasive biomarker for astrocytoma molecular subtyping.
Radiological findings correlate with specific genetic alterations (CDKN2A status).

Outlook

Future research should focus on larger cohorts and prospective designs.
Standardized imaging protocols are crucial for validating T2-FLAIR mismatch utility.
Expanding research to include enhancing astrocytomas will improve generalizability.